Huang M, Ma J, An G, Ye X
PLoS Comput Biol. 2023; 19(12):e1011450.
PMID: 38096269
PMC: 10754467.
DOI: 10.1371/journal.pcbi.1011450.
Hu C, Huang C, Hsu M, Chien H, Wu P, Chen Y
Adv Sci (Weinh). 2023; 10(36):e2301240.
PMID: 37964407
PMC: 10754145.
DOI: 10.1002/advs.202301240.
Nejati-Koshki K, Roberts C, Babaei G, Rastegar M
Cancers (Basel). 2023; 15(10).
PMID: 37345019
PMC: 10216337.
DOI: 10.3390/cancers15102683.
Mehmood S, Aslam S, Dilshad E, Ismail H, Khan A
Cancer Treat Res. 2023; 185:15-47.
PMID: 37306902
DOI: 10.1007/978-3-031-27156-4_2.
Reilly L, Seddighi S, Singleton A, Cookson M, Ward M, Qi Y
Front Aging. 2023; 4:1191993.
PMID: 37168844
PMC: 10165118.
DOI: 10.3389/fragi.2023.1191993.
After a Century of Research into Environmental Mutagens and Carcinogens, Where Do We Stand?.
Vitorino J, Costa P
Int J Environ Res Public Health. 2023; 20(2).
PMID: 36673796
PMC: 9859577.
DOI: 10.3390/ijerph20021040.
Argonaute 2 modulates EGFR-RAS signaling to promote mutant and driven malignancies.
Siebenaler R, Chugh S, Waninger J, Dommeti V, Kenum C, Mody M
PNAS Nexus. 2022; 1(3):pgac084.
PMID: 35923912
PMC: 9338400.
DOI: 10.1093/pnasnexus/pgac084.
Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies.
Caligola S, De Sanctis F, Cane S, Ugel S
Front Genet. 2022; 13:867880.
PMID: 35651929
PMC: 9149246.
DOI: 10.3389/fgene.2022.867880.
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P, Yohe M, Pollard K, Vaseva A, Calizo A, Zhang L
Oncogene. 2022; 41(21):2973-2983.
PMID: 35459782
PMC: 9122815.
DOI: 10.1038/s41388-022-02305-x.
Targeting Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.
Desage A, Leonce C, Swalduz A, Ortiz-Cuaran S
Front Oncol. 2022; 12:796832.
PMID: 35251972
PMC: 8889932.
DOI: 10.3389/fonc.2022.796832.
Computational Prediction of the Pathogenic Status of Cancer-Specific Somatic Variants.
Feizi N, Liu Q, Murphy L, Hu P
Front Genet. 2022; 12:805656.
PMID: 35116056
PMC: 8804317.
DOI: 10.3389/fgene.2021.805656.
The path to the clinic: a comprehensive review on direct KRAS inhibitors.
Kwan A, Piazza G, Keeton A, Leite C
J Exp Clin Cancer Res. 2022; 41(1):27.
PMID: 35045886
PMC: 8767686.
DOI: 10.1186/s13046-021-02225-w.
RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma.
Clark-Garvey S, Kim W
J Clin Invest. 2021; 131(22).
PMID: 34779406
PMC: 8592532.
DOI: 10.1172/JCI154095.
Significance and limitations of the use of next-generation sequencing technologies for detecting mutational signatures.
Abbasi A, Alexandrov L
DNA Repair (Amst). 2021; 107:103200.
PMID: 34411908
PMC: 9478565.
DOI: 10.1016/j.dnarep.2021.103200.
40 Years of RAS-A Historic Overview.
Fernandez-Medarde A, De Las Rivas J, Santos E
Genes (Basel). 2021; 12(5).
PMID: 34062774
PMC: 8147265.
DOI: 10.3390/genes12050681.
A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer.
Heppner D, Eck M
Protein Sci. 2021; 30(8):1535-1553.
PMID: 34008902
PMC: 8284588.
DOI: 10.1002/pro.4125.
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for -Mutant Lung Cancer.
Kohler J, Janne P
Int J Mol Sci. 2021; 22(6).
PMID: 33809660
PMC: 8002337.
DOI: 10.3390/ijms22063025.
Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy.
Ishitsuka Y, Hanaoka Y, Tanemura A, Fujimoto M
Cancers (Basel). 2021; 13(5).
PMID: 33800195
PMC: 7962464.
DOI: 10.3390/cancers13051148.
Tumor Profiling at the Service of Cancer Therapy.
Fernandez-Rozadilla C, Simoes A, LLeonart M, Carnero A, Carracedo A
Front Oncol. 2021; 10:595613.
PMID: 33505911
PMC: 7832432.
DOI: 10.3389/fonc.2020.595613.
Upregulation of Antioxidant Capacity and Nucleotide Precursor Availability Suffices for Oncogenic Transformation.
Zhang Y, Xu Y, Lu W, Ghergurovich J, Guo L, Blair I
Cell Metab. 2020; 33(1):94-109.e8.
PMID: 33159852
PMC: 7846267.
DOI: 10.1016/j.cmet.2020.10.002.